FIG 11.

CDDO-Im treatment partially alleviates inflammation in Sf mice. (A) Regimen of CDDO-Im treatment. WT and Sf mice were injected intraperitoneally with vehicle or CDDO-Im every other day starting 7 or 8 days after birth. Mice were analyzed one day after the final treatment. (B) Immunoblot analysis of the NRF2 protein in representative tissues of WT and Sf mice treated with vehicle or CDDO-Im. α-Tubulin was used as a loading control. (C) Gene expression of Nqo1 in representative organs of vehicle-treated WT (n = 4; white bars), CDDO-Im-treated WT (n = 4; light gray bars), vehicle-treated Sf (n = 4; dark gray bars), and CDDO-Im-treated Sf (n = 4; black bars) mice. The expression levels were normalized to Gapdh expression, and the expression level in vehicle-treated WT mice was set to 1. The values represent the means and SD. *, P < 0.05. (D) HE staining of the skin (pinnae), livers, and lungs of vehicle or CDDO-Im-treated Sf mice. Arrows indicate leukocyte infiltration. (E) Survival curves for Sf mice treated with vehicle (n = 5) or CDDO-Im (n = 5). Treatment was continued throughout the observation period.